When a cancer diagnosis arrives, one of the first questions patients and families ask is: what treatment options are actually available here, close to home? For people in Kerala and northern Malabar, that question now has a more expansive answer than it did even five years ago particularly when it comes to immunotherapy, one of oncology's most significant breakthroughs in decades.
Kerala records 170 cancer cases per lakh population the highest per-capita cancer incidence rate of any state in India, according to a December 2025 reply tabled in the Lok Sabha by the Ministry of Health & Family Welfare.
The silver lining is that Kerala also has some of the country's most diagnostics-aware populations and a growing ecosystem of advanced treatment centres. Immunotherapy which recruits the body's own immune system to detect and destroy cancer cells is now accessible within the state at dedicated facilities.
This article explains what immunotherapy actually involves, who it is right for, and what distinguishes a genuinely specialised cancer immunotherapy centre from a general oncology department that offers it as a line item.
What Is Cancer Immunotherapy and Why Does It Matter?
For most of oncology's history, treatment meant removing tumours surgically, poisoning rapidly dividing cells with chemotherapy, or burning tissue with radiation. These remain important tools, but they carry a fundamental limitation: they don't distinguish very precisely between cancerous and healthy tissue.
Immunotherapy takes a different approach. It works by either amplifying the immune system's natural cancer-detecting abilities or by re-engineering immune cells to target specific markers on tumour surfaces. The immune system, once trained correctly, can be remarkably precise.
The main types in clinical use today:
-
Checkpoint inhibitors: Drugs (like pembrolizumab or nivolumab) that block proteins cancer cells use to "hide" from T-cells. By releasing this brake, the immune system can recognise and attack tumours.
-
Monoclonal antibodies: Lab-manufactured proteins that flag cancer cells for destruction or carry cytotoxic payloads directly to tumour sites.
-
CAR-T cell therapy: A patient's own T-cells are extracted, genetically re-engineered in a lab to carry chimeric antigen receptors (CARs) targeting specific cancer markers, then reinfused.
-
Cytokine therapy: Large quantities of immune-signalling proteins (interferons, interleukins) are introduced to boost the overall immune response.
-
Cancer vaccines: Therapeutic (not preventive) vaccines designed to train the immune system to recognise tumour-specific antigens.
Unlike chemotherapy, immunotherapy does not always produce immediate tumour shrinkage response patterns are different, and treatment monitoring requires specialised imaging and biomarker tracking over time. This is one reason a dedicated clinic matters.
Who Is a Candidate for Immunotherapy?
Candidacy is determined by several clinical factors, and this is one area where the expertise of the treating team is decisive. Blanket eligibility does not exist, a patient whose cancer responds dramatically to checkpoint inhibitors may be sitting next to someone with a similar diagnosis for whom those same drugs are largely ineffective.
| Factor | Why it matters |
|---|---|
| Tumour type & stage | Some cancers (melanoma, NSCLC, certain lymphomas, renal cell carcinoma) have high response rates to checkpoint inhibitors; others are still investigational |
| PD-L1 expression levels | Biomarker testing reveals how likely tumour cells are to respond to PD-1/PD-L1 inhibitors |
| Tumour Mutational Burden (TMB) | High TMB tumours produce more neoantigens, making them more "visible" to the immune system and more responsive |
| Mismatch Repair (MMR) status | MMR-deficient tumours accumulate mutations that generate immune targets, a key predictor of response |
| Prior treatment history | Some immunotherapies are first-line; others are reserved for relapsed/refractory disease |
| Autoimmune history | Pre-existing autoimmune conditions can amplify immune-related adverse events from checkpoint inhibitors |
Why Access to a Dedicated Centre Is Critical?
Kerala's high cancer incidence partly reflects its excellent diagnostic infrastructure the state's healthcare literacy means more cancers are caught earlier, and more are formally counted. But it also means demand for advanced treatment is high and growing.
the distinction between a hospital that offers immunotherapy and one that has built its entire sub-speciality infrastructure around it becomes clinically meaningful not just a marketing distinction.
What a Dedicated Immunotherapy Centre Actually Looks Like?
When evaluating any immunotherapy programme, certain structural features matter independently of the branding used to describe them.
Integrated sub-speciality teams
Effective immunotherapy delivery requires hemato-oncologists, medical oncologists, transplant physicians, and surgical oncologists operating under shared protocols, not as separate departments that communicate by referral. Multi-disciplinary tumour boards that review each case before and during treatment are a hallmark of centres with serious immunotherapy programmes.
Dedicated immunotherapy clinic with in-house lab
Immunotherapy drugs are biologically complex and require monitoring for immune-related adverse events (irAEs), conditions like pneumonitis, colitis, or endocrinopathies that can emerge weeks or months after treatment starts. A clinic with on-site laboratory services and transfusion facilities can respond faster to these complications than one that relies on external processing.
Bone Marrow Transplant capability
For haematological malignancies leukaemias, lymphomas, multiple myeloma immunotherapy and bone marrow transplant (BMT) are often used in sequence or combination. A centre that can offer both under one roof, using bone marrow, peripheral blood stem cells, and cord blood stem cells, provides continuity of care that matters when treatment protocols evolve mid-course.
Disease-specific clinics
Generic oncology departments handle the breadth of cancer presentations. Specialised centres add disease-specific clinics for myeloma, for example, where protocols, drug selection, and monitoring are refined by volume of experience with that particular malignancy.
Paediatric oncology capacity
Childhood cancers respond differently to immunotherapy than adult malignancies and require paediatric oncologists with sub-speciality training. Centres that combine adult and paediatric oncology under the same immunotherapy framework offer continuity for families navigating both.
For patients exploring advanced cancer immunotherapy and blood cancer treatment options in North Kerala, understanding how a hospital structures its oncology services can make a significant difference in long-term care continuity.
Meitra Hospital's Centre for Blood Diseases, BMT & Cancer Immunotherapy
Meitra Hospital has developed a dedicated Centre for Blood Diseases, Bone Marrow Transplant (BMT), and Cancer Immunotherapy that brings multiple oncology specialties together under a coordinated care model.
Instead of treating immunotherapy as a standalone service, the centre integrates medical oncology, haematology, surgical oncology, BMT, and immunotherapy within a shared treatment framework.
This multidisciplinary structure is particularly important for cancers that require long-term monitoring, biomarker-driven treatment decisions, and coordinated follow-up care.
Moreover, Meitra’s in-house labs are NABL-accredited (ISO 15189), ensuring that diagnostic results are accurate and recognized for international insurance and government scheme approvals.
Key Areas of Specialised Cancer Care
The centre includes several specialised services designed to support both adult and paediatric cancer patients, including:
- Dedicated cancer immunotherapy and haematology clinics
- In-house laboratory and transfusion support for monitoring-intensive therapies
- Bone Marrow Transplant (BMT) services
- A specialised Myeloma Clinic for multiple myeloma management
- Paediatric oncology care led by DM-trained specialists
- Coordinated multidisciplinary treatment planning across oncology departments
A Centre Built Around Collaborative Oncology Care
Meitra Hospital's broader Centres of Excellence model was established to encourage close coordination between medical and surgical departments under unified specialty leadership. In oncology, this collaborative structure supports faster decision-making, disease-specific treatment planning, and continuity across different stages of cancer care.
What distinguishes the centre in practice is the combination of biomarker-informed treatment strategies, disease-focused clinics, transplant support, paediatric oncology expertise, and integrated cancer care pathways within a single treatment environment.
For patients outside Calicut, Meitra offers Advanced Tele-Oncology and virtual Second Opinions.
Upload your PET-CT and pathology reports via our secure portal for a review by our MDT board.
For international patients from the Middle East and South Asia, Meitra provides comprehensive concierge services, including visa documentation and airport transfers.
Speak to a Cancer Specialist at Meitra Hospital Our Centre for Blood Diseases, BMT & Cancer Immunotherapy team reviews each case individually, before recommending any treatment path. Book a consultation directly.